Enhancing the effect of secreted cyclophilin B on immunosuppressive activity of cyclosporine.
BACKGROUND
Cyclophilin B (CyPB) is a cyclosporine (CsA)-binding protein, located within intracellular vesicles and secreted in biological fluids. In previous works, we reported that CyPB specifically interacts with the T-cell membrane and potentiates the ability of CsA to inhibit CD3-induced proliferation of T lymphocytes.


METHODS
CyPB levels were measured in plasma from healthy donors and transplant patients. The role of extracellular CyPB on the distribution and activity of CsA was investigated first by studies on the uptake of free and CyPB-complexed drug by blood cells, and second by studies on the inhibitory effects of these two compounds on the CD3-induced proliferation of peripheral blood mononuclear cells.


RESULTS
A significant increase in plasma CyPB level was observed for CsA-treated patients (13+/-6.4 nM, n=42) in comparison with untreated donors (4.3+/-2.1 nM, n=34). In vitro, extracellular CyPB dose dependently modified CsA distribution between plasma, erythrocyte, and lymphocyte contents, by both retaining the complexed drug extracellularly and promoting its specific accumulation within peripheral blood mononuclear cells. Moreover, the enhanced ability of CyPB-complexed CsA to suppress CD3-induced T-cell proliferation was preserved in the presence of other blood cells, implying specific targeting of the drug to sensitive cells. Furthermore, although a large interindividual variability of sensitivity to the drug was confirmed for 18 individuals, we found that CyPB potentiated the activity of CsA in restoring a high sensitivity to the immunosuppressant.


CONCLUSIONS
These results suggest that plasma CyPB may contribute to the acceptance and the good maintenance of organ transplantation by enhancing the immunosuppressive activity of CsA through a receptor-mediated incorporation of CyPB-complexed CsA within peripheral blood lymphocytes.
Denys
A
A
Laboratoire de Chimie Biologique, Unité Mixte de Recherche no 111 du Centre National de la Recherche Scientifique, Université des Sciences et Technologies de Lille, France.
Allain
F
F
Masy
E
E
Dessaint
J P
JP
Spik
G
G
D000328:Adult; D000591:Amino Acid Isomerases / Q000096:biosynthesis / Q000097:blood*; D015153:Blotting, Western; D002352:Carrier Proteins / Q000096:biosynthesis / Q000097:blood*; D021983:Cyclophilins; D016572:Cyclosporine / Q000097:blood / Q000627:therapeutic use*; D004797:Enzyme-Linked Immunosorbent Assay; D004912:Erythrocytes / Q000276:immunology / Q000378:metabolism; D005260:Female; D016027:Heart Transplantation / Q000276:immunology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000097:blood / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology*; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D019696:Peptidylprolyl Isomerase; D012016:Reference Values
D002352:Carrier Proteins; D007166:Immunosuppressive Agents; C081786:cyclophilin B; D016572:Cyclosporine; D000591:Amino Acid Isomerases; D021983:Cyclophilins; D019696:Peptidylprolyl Isomerase